

University of Groningen

## Novel therapies in heart failure

Liu, Licette Cécile Yang

**IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below.**

*Document Version*

Publisher's PDF, also known as Version of record

*Publication date:*

2016

[Link to publication in University of Groningen/UMCG research database](#)

*Citation for published version (APA):*

Liu, L. C. Y. (2016). *Novel therapies in heart failure*. Rijksuniversiteit Groningen.

**Copyright**

Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).

The publication may also be distributed here under the terms of Article 25fa of the Dutch Copyright Act, indicated by the "Taverne" license. More information can be found on the University of Groningen website: <https://www.rug.nl/library/open-access/self-archiving-pure/taverne-amendment>.

**Take-down policy**

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

*Downloaded from the University of Groningen/UMCG research database (Pure): <http://www.rug.nl/research/portal>. For technical reasons the number of authors shown on this cover page is limited to 10 maximum.*



# **Novel Therapies in Heart Failure**

Licette C.Y. Liu

Licette Cécile Yang Liu  
Novel Therapies in Heart Failure

Copyright © 2016, Licette C.Y. Liu

All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, without prior permission of the author.

Layout and printed by: Optima Grafische Communicatie, Rotterdam, the Netherlands  
Cover design: Liza Renee - Illustratie & Vormgeving, Groningen, the Netherlands.

Financial support for the publication of this thesis by the following institutes or companies is gratefully acknowledged:

University of Groningen, Graduate School of Medical Sciences, Pfizer B.V., Biotronic Nederland B.V., Servier Nederland Farma B.V., Amgen B.V., Daiichi Sankyo Nederland B.V., ChipSoft B.V., Bayer B.V.

ISBN: 978-94-6169-895-7

E-pub ISBN: 978-94-6169-898-8



rijksuniversiteit  
 groningen

# Novel Therapies in Heart Failure

## Proefschrift

ter verkrijging van de graad van doctor aan de  
Rijksuniversiteit Groningen  
op gezag van de  
rector magnificus prof. dr. E. Sterken  
en volgens besluit van het College voor Promoties.

De openbare verdediging zal plaatsvinden op

woensdag 29 juni 2016 om 14.30 uur

door

**Licette Cécile Yang Liu**

geboren op 25 februari 1988  
te Hoogezand-Sappemeer

**Promotor**

Prof. dr. A.A. Voors

**Copromotor**

Dr. P. van der Meer

**Beoordelingscommissie**

Prof. dr. W.H. van Gilst

Prof. dr. P.A. de Graeff

Prof. dr. M. Metra

**Paranimfen**      drs. A. Fluitman  
                         drs. M.A. de Vries

Financial support by the Dutch Heart Foundation for the publication of this thesis is gratefully acknowledged.





*To begin, begin*

William Wordsworth (1770-1850)

---

## TABLE OF CONTENTS

---

Introduction	13
<b>Part I: Precision Medicine in Heart Failure</b>	
Chapter 1 A Novel Approach to Drug Development in Heart Failure: Towards Personalized Medicine	33
Chapter 2 Effects of Serelaxin in Acute Heart Failure Patients with Renal Impairment: Results from RELAX-AHF	51
Chapter 3 Identifying Subpopulations with Distinct Response to Treatment Using Plasma Biomarkers in Acute Heart Failure: Results from the PROTECT trial	71
<b>Part II: Novel Drugs for the Treatment of Heart Failure with Preserved Ejection Fraction</b>	
Chapter 4 Renal Effects of the Angiotensin Receptor Neprilysin Inhibitor LCZ696 in Patients with Heart Failure and Preserved Ejection Fraction	103
Chapter 5 Effects of Sildenafil on Invasive Hemodynamics and Exercise Capacity in Heart Failure Patients with Preserved Ejection Fraction and Pulmonary Hypertension: A Randomized Controlled Trial	123
Chapter 6 Effects of Sildenafil on Cardiac Structure and Function, Cardiopulmonary Exercise Testing and Health-Related Quality-of-Life Measures in Heart Failure Patients with Preserved Ejection Fraction and Pulmonary Hypertension	153

### **Part III: Drug Evaluations of Novel Drugs for the Treatment of Heart Failure with Reduced Ejection Fraction**

Chapter 7	Finerenone: Third Generation Mineralocorticoid Receptor Antagonist for the Treatment of Heart Failure and Diabetic Kidney Disease	179
Chapter 8	Omecamtiv Mecarbil: a Novel Cardiac Myosin Activator for the Treatment of Heart Failure	203
	General Discussion and Future Directions	225
	Nederlandse Samenvatting	245
	Dankwoord	255
	Curriculum Vitae	261
	List of Publications	263